The natural history of SMA has been transformed by the approval of disease-modifying therapies, starting with nusinersen, a synthetic antisense oligonucleotide that alters the splicing of SMN2 pre-mRNA and promotes the production of functional SMN protein [9]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.